11 active not recruiting. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| Iptacopan in Patients With ANCA Associated Vasculitis Iptacopan, Placebo, Rituximab - Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 84 | 2024-08-05 | 2026-10-15 |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Sparsentan - ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Active not recruiting | University of Edinburgh | 32 | 2022-12-08 | 2026-08-26 |
| TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Trimethoprim Sulfamethoxazole - Granulomatosis With Polyangiitis, Wegener Granulomatosis | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 8 | 2019-03-27 | 2026-09-25 |
| Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Doxycycline, Placebo - Kawasaki Disease, Coronary Aneurysm | Phase 2 | Active not recruiting | Hawaii Pacific Health | 26 | 2013-10-01 | 2026-06-03 |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Autoimmune Disease, Neurologic Autoimmune Disease | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2008-06-01 | 2026-02-27 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Granulomatosis with Polyangiitis (4) · Churg-Strauss Syndrome (3) · Microscopic Polyangiitis (3) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Cardiovascular Diseases (1) · Coronary Aneurysm (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Kidney Diseases (1) · Lambert-Eaton Myasthenic Syndrome (1) · Lupus Nephritis (1) · Mucocutaneous Lymph Node Syndrome (1)
Vascular Diseases (11) · Cardiovascular Diseases (10) · Immune System Diseases (10) · Skin Diseases (10) · Skin Diseases, Vascular (10) · Skin and Connective Tissue Diseases (10) · Autoimmune Diseases (9) · Systemic Vasculitis (9) · Brain Diseases (4) · Central Nervous System Diseases (4) · Cerebrovascular Disorders (4) · Hemic and Lymphatic Diseases (4) · Lung Diseases (4) · Lung Diseases, Interstitial (4)
Prednisone (2) · Antilymphocyte Serum (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Doxycycline (1) · Etoposide (1) · Glucocorticoids (1) · Immunoglobulins, Intravenous (1) · Infliximab (1) · Melphalan (1) · Methylprednisolone (1) · Peripheral Blood Stem Cell Transplantation (1) · Rituximab (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1)
Novartis Pharmaceuticals (2) · Alpine Immune Sciences, Inc. (1) · Fred Hutchinson Cancer Center (1) · Hawaii Pacific Health (1) · Imperial College London (1) · Marcela V. Maus, M.D.,Ph.D. (1) · NS Pharma, Inc. (1) · Renmin Hospital of Wuhan University (1) · University of Edinburgh (1) · University of Pennsylvania (1)
United States (8) · United Kingdom (5) · Australia (2) · Canada (2) · China (2) · France (2) · Germany (2) · Japan (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Czechia (1) · Denmark (1)
Andras Bratincsak, MD PhD (1) · Leona Holmberg (1) · Neeraj Dhaun (1) · Salman Siddiqui, MBBS (1) · Sebastian Unizony, MD (1)
2023 (1)